• Grey Facebook Icon
  • Grey Twitter Icon
  • Grey YouTube Icon

©2019 by Autistalline

Company Information

Company Backgrounder

Autistalline’s dual missions are to improve quality of life and reduce cost of care for individuals with autism through meltdown eliminating eyewear, and to donate 10% of our profits to ministry and to the betterment of disadvantaged groups within our society.


What Autistalline Glasses Do

Autistalline glasses trick the autistic brain into eliminating meltdowns and sensory overload for the entire duration Autistalline Glasses are worn. Additional effects include decreased stress hormones production, decreased inflammation levels and lower incidences of GI tract issues.


How Autistalline Glasses Work

Multiple published studies confirm the prevalence of sensory, visual and neural processing impairments in individuals with Autism Spectrum Disorder (ASD). One study found 95% of the sample children with ASD demonstrated some degree of sensory processing dysfunction.


Visual, sensory, auditory and neural processing impairment may be a leading contributing factor to a host of symptoms affecting behavior and function of an individual with ASD, including but not limited to autism meltdown, sensory overload, brain pain, increased cortisol levels, increased inflammation markers, increased GI tract issues and auditory and face blindness.


Autistalline glasses work by blocking specific wavelengths of light from passing through the lens and entering the eye. We hypothesize the autistic brain converts the modified light information into a modified electrical signal before it is sent to the brain. This modified electrical signal tricks the autistic brain into efficiently processing incoming data which eliminates the precursors that appear in the autistic brain prior to sensory overload and meltdown.


This modified electrical signal only affects the Non-Image Forming (NIF) visual pathway system, therefore, there is no change to vision or what is recognized as visual data as seen by the eye and interpreted by the brain. Since 70% of the body’s sensory receptors are located in the eye, even if every non-visual sensory receptor (auditory, touch, smell, emotional, etc) were all simultaneously, heavily stimulated at the exact same time, only 30% of the body’s total sensory receptors would be activated. This implies meltdowns due to emotional overwhelm or auditory overload can be influenced and/or overpowered by visual data.


Autistalline glasses are not a cure, correction, or fix for Autism Spectrum Disorder. These statements have not yet been approved by the FDA. 3rd party peer review labs will need to run multiple verification experiments before Autistalline glasses will be sold to the public. We are currently in development and testing.



We are in pre-development of our 2nd glasses prototype. These 2nd prototype glasses will contain a clear glass lens and will be non-prescription. These prototype glasses will be used in our clinical trials and will be available for purchase on Autistalline's website and through select retailers in the United States by mid 2020.

Products and Future Products

Glasses, contact lenses, and intraocular lenses will be available with and without vision prescription. In the long term, additional glasses for various health conditions will be also be available. 


Research & Science

Since this exact frequency of selective light filtering for the use of autism meltdown elimination has never been studied before, there are no previously established public works to reference. We’ve created a document called, Current Similar Domain Scientific Works detailing scientific and anecdotal works that point in the direction of evidence of this concept. This document is available upon request. We are currently in the process of applying for the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grants, and plan on being the first to publish peer-reviewed findings on Specific Light Filtering for Autism Meltdown and Sensory Overload Elimination.



The Centers for Disease Control and Prevention (CDC) estimates ASD affected 1 in 59 individuals (1.5M people) in the United States, and 200M people worldwide had autism. EpidemicAnswers.org projects the rate of autism will reach 25% of the population in 2033.